How to Transition from Single-Gene Pharmacogenetic Testing to Preemptive Panel-Based Testing: A Tutorial.
Antineoplastic Agents
/ adverse effects
Clinical Decision-Making
Decision Support Systems, Clinical
Decision Support Techniques
Drug Interactions
Gene Expression Profiling
Genetic Counseling
Humans
Pharmacogenetics
Pharmacogenomic Testing
Pharmacogenomic Variants
Polypharmacy
Precision Medicine
Predictive Value of Tests
Program Development
Program Evaluation
Journal
Clinical pharmacology and therapeutics
ISSN: 1532-6535
Titre abrégé: Clin Pharmacol Ther
Pays: United States
ID NLM: 0372741
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
04
03
2020
accepted:
08
05
2020
pubmed:
28
5
2020
medline:
26
5
2021
entrez:
28
5
2020
Statut:
ppublish
Résumé
There have been significant advancements in precision medicine and approaches to medication selection based on pharmacogenetic results. With the availability of direct-to-consumer genetic testing and growing awareness of genetic interindividual variability, patient demand for more precise, individually tailored drug regimens is increasing. The University of Florida (UF) Health Precision Medicine Program (PMP) was established in 2011 to improve integration of genomic data into clinical practice. In the ensuing years, the UF Health PMP has successfully implemented several single-gene tests to optimize the precision of medication prescribing across a variety of clinical settings. Most recently, the UF Health PMP launched a custom-designed pharmacogenetic panel, including pharmacogenes relevant to supportive care medications commonly prescribed to patients undergoing chemotherapy treatment, referred to as "GatorPGx." This tutorial provides guidance and information to institutions on how to transition from the implementation of single-gene pharmacogenetic testing to a preemptive panel-based testing approach. Here, we demonstrate application of the preemptive panel in the setting of an adult solid tumor oncology clinic. Importantly, the information included herein can be applied to other clinical practice settings.
Identifiants
pubmed: 32460360
doi: 10.1002/cpt.1912
pmc: PMC7704727
mid: NIHMS1614274
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
557-565Subventions
Organisme : NHGRI NIH HHS
ID : U01 HG007269
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001427
Pays : United States
Informations de copyright
© 2020 The Authors Clinical Pharmacology & Therapeutics © 2020 American Society for Clinical Pharmacology and Therapeutics.
Références
J Mol Diagn. 2018 May;20(3):269-276
pubmed: 29474986
BMC Res Notes. 2018 Jan 08;11(1):8
pubmed: 29310721
Clin Pharmacol Ther. 2017 Jul;102(1):37-44
pubmed: 27997040
Clin Pharmacol Ther. 2014 Dec;96(6):652-4
pubmed: 25399713
Contemp Clin Trials. 2018 May;68:7-13
pubmed: 29535047
J Clin Epidemiol. 2016 Apr;72:107-15
pubmed: 26628336
Clin Transl Sci. 2018 Mar;11(2):175-181
pubmed: 29351371
MDM Policy Pract. 2019 Aug 17;4(2):2381468319864337
pubmed: 31453360
Nature. 2015 Oct 15;526(7573):343-50
pubmed: 26469045
Expert Opin Drug Metab Toxicol. 2018 Apr;14(4):447-460
pubmed: 29620484
J Transl Med. 2018 Apr 11;16(1):92
pubmed: 29642909
Technol Cancer Res Treat. 2019 Jan 1;18:1533033819873924
pubmed: 31533552
N Engl J Med. 2010 Jul 22;363(4):301-4
pubmed: 20551152
Clin Pharmacol Ther. 2013 Sep;94(3):317-23
pubmed: 23698643
Indian J Palliat Care. 2017 Oct-Dec;23(4):445-450
pubmed: 29123353
J Mol Diagn. 2019 Sep;21(5):746-755
pubmed: 31075510
Eur J Pharmacol. 2000 Dec 27;410(2-3):121-130
pubmed: 11134664
Clin Pharmacol Ther. 2011 May;89(5):662-73
pubmed: 21412232
Pharmacotherapy. 2017 Sep;37(9):1014-1022
pubmed: 28699700
Clin Pharmacol Ther. 2018 Oct;104(4):664-674
pubmed: 29280137
Pharmacogenomics. 2014 Aug;15(11):1405-16
pubmed: 25303292
Clin Pharmacol Ther. 2015 Jul;98(1):19-24
pubmed: 25801146
Mayo Clin Proc. 2017 Nov;92(11):1711-1722
pubmed: 29101939
Clin Pharmacol Ther. 2014 Mar;95(3):269-80
pubmed: 24136381
Clin Transl Sci. 2016 Oct;9(5):233-245
pubmed: 27214750
Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):1130-3
pubmed: 12376522
Am J Med Genet C Semin Med Genet. 2014 Mar;166C(1):76-84
pubmed: 24616408
Clin Transl Sci. 2020 Jan;13(1):116-124
pubmed: 31647186
Clin Pharmacol Ther. 2015 Aug;98(2):127-34
pubmed: 25974703
Clin Pharmacol Ther. 2014 Apr;95(4):376-82
pubmed: 24458010
Clin Pharmacol Ther. 2011 Mar;89(3):464-7
pubmed: 21270786
Clin Pharmacol Ther. 2016 Feb;99(2):154-6
pubmed: 26440500
BMC Res Notes. 2018 Jun 14;11(1):382
pubmed: 29898767
Clin Pharmacol Ther. 2018 May;103(5):787-794
pubmed: 29377064
Genet Med. 2017 Apr;19(4):421-429
pubmed: 27657685
Annu Rev Pharmacol Toxicol. 2015;55:89-106
pubmed: 25292429
Clin Pharmacol Ther. 2017 Jul;102(1):45-51
pubmed: 27981572
Clin Pharmacol Ther. 2017 Aug;102(2):213-218
pubmed: 28002639
Clin Pharmacol Ther. 2017 Sep;102(3):502-510
pubmed: 28090649
Clin Transl Sci. 2019 Mar;12(2):172-179
pubmed: 30341969
Pharmacogenomics. 2019 Oct;20(15):1103-1112
pubmed: 31588877
Clin Transl Sci. 2020 May;13(3):473-481
pubmed: 31758664